High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals

European Journal of Cardio-thoracic Surgery

Volumn 41, Issue 6, 2012, Pages

  Cortes Dericks, Lourdes ^a   Galetta, Domenico ^b   Spaggiari, Lorenzo ^b   Schmid, Ralph Alexander ^a   Karoubi, Golnaz ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Adenocarcinoma; Aldehyde dehydrogenase (ALDH); Cancer stem cells; Lung cancer; Octamer 4 (OCT4A); Prominin 1 (CD133)

Indexed keywords

ALDEHYDE DEHYDROGENASE; BMI1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; MESSENGER RNA; OCTAMER BINDING TRANSCRIPTION FACTOR 4A; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR VOLUME; ADENOCARCINOMA; BIOSYNTHESIS; CANCER GRADING; CANCER STAGING; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; ALDEHYDE DEHYDROGENASE; ANTIGENS, CD; FEMALE; GLYCOPROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84865352491     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs170     Document Type: Article

References (25)

1. van Klaveren RJ, van't Westeinde SC, de Hoop BJ, Hoogsteden HC. Stem cells and the natural history of lung cancer: implications for lung cancer screening. Clin Cancer Res 2009;15:2215-8.
2. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011;7:292-306.
3. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R et al. A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer 2010;1:908-16.
4. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelialmesenchymal transdifferentiation. Cancer Res 2010;70:10433-44.
5. Takahashi S, Kamiyama T, Tomaru U, Ishizu A, Shida T, Osaka M et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010;24:1201-12.
6. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009;18:1127-34.
7. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009;106: 16281-86.
8. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009;7:330-8.
9. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010;34:1193-8.
10. Boonstra MC, Verspaget HW, Ganesh S, Kubben FJ, Vahrmeijer AL, van de Velde CJ et al. Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr Pharm Des 2011;17:1890-910.
11. Li F, Zeng H, Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 2010;28:1458-62.
12. Almasi CE, Christensen IJ, Hoyer-Hansen G, Dano K, Pappot H, Dienemann H et al. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis. Lung Cancer 2011;74: 510-5.
13. Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J et al. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 2008;134: 1037-42.
14. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007;26: 39-57.
15. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer 2008;59:340-9.
16. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010;70:9937-48.
17. Singh S, Dirks PB. Brain tumor stem cells: identification and concepts. Neurosurg Clin N Am 2007;18:31-8, viii.
18. Xu YH, Zhang GB, Wang JM, Hu HC. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J 2010;31:980-6.
19. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010;126:950-8.
20. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 2010;4:32-42.
21. Karoubi G, Cortes-Dericks L, Gugger M, Galetta D, Spaggiari L, Schmid R. Atypical expression and distribution of embryonic stem cell marker, OCT4, in human lung adenocarcinoma. J Surg Oncol 2010;102: 689-98.
22. Kim RJ, Nam JS. OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res 2011;27:147-52.
23. Zhang XY, Dong QG, Huang JS, Huang AM, Shi CL, Jin B et al. The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. J Surg Oncol 2010;102:856-62.
24. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008;3:e2637.
25. Lagiou P, Trichopoulos D. Inflammatory biomarkers and risk of lung cancer. J Natl Cancer Inst 2011;103:1073-5.